跳至主要内容
临床试验/EUCTR2010-021092-89-IT
EUCTR2010-021092-89-IT进行中(未招募)不适用

Cisplatin and Alimta with panitumumaB for Advanced non-squamous Lung cAncer (CABALA Trial): a SICOG multicenter, phase II trial - CABALA

SOUTHERN ITALY COOPERATIVE ONCOLOGY GROUP0 个研究点开始时间: 2010年9月29日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Histological diagnosis of previously untreated, non-squamous, NSCLC, EGFR + (FISH) - Stage IIIb or IV - Age 18-75 - PS ECOG 0-1 - At least 1 measurable lesion (RECIST v. 1.1) - Good main organs function - Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Past (within 5 years of study entry) or concurrent neoplasm other than adequately managed in situ carcinoma of the cervix and/or basal cell skin cancer - Clinically detectable brain metastases - Concurrent treatment with other chemotherapeutic, hormonal or biologic antineoplastic agents. - Prior exposure to cisplatin in the adjuvant setting - Previous chemotherapy for metastatic disease - Previous radiotherapy - Clinically significant disease

研究者

发起方
SOUTHERN ITALY COOPERATIVE ONCOLOGY GROUP

相似试验

进行中(未招募)
不适用
Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with bile duct cancer - a randomized clinical phase II study - PiCCA Studycholangiocarcinoma / gall bladder carcinomaMedDRA version: 15.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: LLTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-018850-11-DEMedizinische Hochschule Hannover (MHH)
进行中(未招募)
1 期
Tratamiento con Alimta (Pemetrexed) y cisplatino como tratamiento neoadyuvante en el cancer no microcitico de pulmoCancer de Pulmon no Microcitico, Pirmera Linea
EUCTR2005-002279-33-ESilly S.A.44
进行中(未招募)
1 期
Phase 1/2 Study of Biweekly ALIMTA plus Cisplatin in patients with Locally Advanced, non-Resectable or Metastatic Urothelial Cancerocally Advanced, non-Resectable or Metastatic Urothelial Cancer
EUCTR2004-004149-16-ESilly S.A.57
进行中(未招募)
不适用
Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Gemcitabine or Gemcitabine combinatio
EUCTR2005-003855-11-DEKlinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze75
已完成
不适用
Paclitaxel plus carboplatin for advanced or recurrent carcinosarcoma of the uterus in Japan.advanced or recurrent carcinosarcoma
JPRN-UMIN000008390Gynecology, Tohoku University Hospital35